GeneDx Holdings (WGS) Research & Development (2020 - 2026)

GeneDx Holdings (WGS) has reported Research & Development for 7 consecutive years, with $19.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 30.35% year-over-year to $19.7 million in Q2 2026; TTM through Jun 2026 was $90.1 million, a 44.49% increase from a year earlier, with the FY2025 full-year figure at $88.4 million, up 31.22% from the prior year.
• Research & Development was $19.7 million for Q2 2026 at GeneDx Holdings, down from $19.8 million in the prior quarter.
• Over five years, Research & Development peaked at $34.4 million in Q3 2022 and troughed at $12.6 million in Q1 2025.
• A 5-year average of $20.6 million and a median of $17.4 million in 2023 frame the typical range for Research & Development.
• The widest YoY moves for Research & Development: up 76.74% in 2022, down 51.76% in 2022.
• Over 5 years, Research & Development stood at $29.2 million in 2022, then slumped by 48.91% to $14.9 million in 2023, then advanced by 18.33% to $17.7 million in 2024, then soared by 53.49% to $27.1 million in 2025, then fell by 27.55% to $19.7 million in 2026.
• The last three Research & Development figures came in at $19.7 million (Q2 2026), $19.8 million (Q1 2026), and $27.1 million (Q4 2025), per Business Quant data.